Tyrosine kinase inhibitors and the thyroid

Area of Science:

• Oncology
• Pharmacology

Background:

• Protein tyrosine kinase inhibitors (TKIs) represent a significant advancement in targeted cancer therapy.
• Conventional treatments are often ineffective for advanced or metastatic differentiated and medullary thyroid carcinomas.

Purpose of the Study:

• To review the emerging role of novel therapies, particularly TKIs targeting angiogenesis, in treating advanced thyroid carcinoma.
• To highlight the efficacy and safety profiles of these agents, including their impact on thyroid function.

Main Methods:

• Review of clinical trial data for novel angiogenesis-targeting agents in differentiated and medullary thyroid carcinomas.
• Analysis of reported response rates, disease stabilization, and adverse effects, with a focus on vascular endothelial growth factor receptor inhibitors.

Main Results:

• Partial response rates up to 30% observed in single-agent studies, with prolonged disease stabilization being a more common outcome.
• Vascular endothelial growth factor receptor inhibitors, such as sorafenib and sunitinib, show promising preliminary results.
• Adverse effects on thyroid function and hormone metabolism necessitate regular monitoring.

Conclusions:

• Novel TKIs targeting angiogenesis offer promising therapeutic options for patients with advanced thyroid carcinoma unresponsive to conventional treatments.
• Clinical trial participation is emphasized for accessing these novel agents.
• Proactive monitoring of thyroid function is essential for patients undergoing TKI therapy.